UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts

 

UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts
Avatar

ASH Updates on cHL: 2L Pembro + GVD, Brentuximab Vedotin & Checkpoint Blockade Combination in High Risk Patients

By UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts FEATURING Peter Riedell
By UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts FEATURING Peter Riedell
109 views
March 5, 2021
0 Comments
Login to view comments. Click here to Login

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay
Videos
05:11
UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts

ASH Updates on R/R MM: How to Choose Amongst Available Regimens at 1…

Feat. B. Derman
21:25
UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts

ASH Updates on Frontline MM: What Is the Optimal Induction Regimen? …

Feat. B. Derman
11:49
UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts

35 y/o Male With Newly Diagnosed ALL: What Findings Are Traditionall…

Feat. A. Duvall, P. Riedell, B. Derman, S. Kosuri
15:12
UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts

63 y/o Male With MCL: What Initial Therapy to Choose? What Would Be …

Feat. A. Duvall, P. Riedell, B. Derman, S. Kosuri
17:01
UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts

Newly Diagnosed MM Case Discussion: Classifying Patient Risk, and Ap…

Feat. A. Duvall, P. Riedell, B. Derman, S. Kosuri
14:37
UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts

Expert Analysis of a Primary Myelofibrosis Case: What Tests Could Be…

Feat. A. Duvall, P. Riedell, B. Derman, S. Kosuri
24:46
UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts

ASH Updates on Non-Malignant Hematology: Mycophenolate for ITP, CTX0…

Feat. M. Thirman
34:05
UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts

ASH Practice Changing Updates in AML: Maintenance Oral Aza, Lower In…

Feat. C. DiNardo
30:26
UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts

ASH Advances in Cellular Therapy: Tisa-Cel in R/R B-ALL, Blinatumoma…

Feat. A. Jakubowiak
27:46
UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts

ASH Highlights on High-Risk MDS in HMA Era: Oral HMAs, BCL2 Inhibiti…

Feat. O. Odenike
16:45
UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts

Best of ASH on SCT in Leukemias: Who Should Be Referred Early for AS…

Feat. S. Kosuri
16:23
UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts

ASH Update on SCT for Myeloid and Lymphoid Leukemias: Apamistamab as…

Feat. S. Kosuri
17:31
UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts

ASH Updates on SoC in Lymphomas: How Beneficial Are Newly Approved B…

Feat. P. Riedell
07:31
UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts

ASH Updates on cHL: 2L Pembro + GVD, Brentuximab Vedotin & Check…

Feat. P. Riedell
06:44
UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts

ASH Updates on SoC in R/R MCL: How Active Are Novel BTKi & CAR-T…

Feat. P. Riedell